Wilms' tumor

Stop & Shop Fights Pediatric Cancer with Kick Off of ‘Help Cure Childhood Cancer’ Campaign

Retrieved on: 
Thursday, February 29, 2024
Breast cancer, Hospital, Acute lymphoblastic leukemia, MSK, Bruise, Doctor of Philosophy, MD, The Jimmy Fund, Physician, Malignancy, Friends, Cancer, Parent, Skin, Hope, Stop & Shop, EMPOWER, T-cell acute lymphoblastic leukemia, Dana–Farber Cancer Institute, Radiation, Mouth, Stop, Health, Kidney cancer, Adolescence, COVID-19, Wilms' tumor, Leukemia, Young adult, Patient, Family, Pediatrics, Child, Rhabdomyosarcoma, Estate (law), Research, Cheek

Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.

Key Points: 
  • Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.
  • 100% of proceeds will benefit the two hospitals to assist in their pioneering pediatric cancer treatment and care.
  • The Stop & Shop Pediatric Brain Tumor Clinic at Dana-Farber Cancer Institute is a world-renowned destination for children with malignant and non-malignant brain tumors.
  • “Stop & Shop’s dedication and generous support of pediatric cancer continues to help fund critical research and care,” said Scott Armstrong, MD, PhD, chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute.

Pan-Mass Challenge Donates Unprecedented $72 Million to Dana-Farber Cancer Institute

Retrieved on: 
Monday, November 13, 2023
Oropharyngeal cancer, M&T Bank, The Jimmy Fund, Dana–Farber Cancer Institute, Pan-Mass Challenge, Patient, Wilms' tumor, Cancer, Volunteering, Boston Red Sox, PMC, Pharmaceutical industry, Property management, Boston, MD

BOSTON, Nov. 13, 2023 /PRNewswire/ -- Today, the Pan-Mass Challenge (PMC), the world's single most successful athletic fundraiser, announced its largest gift ever for cancer research, treatment, and care at the world-renowned Dana-Farber Cancer Institute, a record-breaking $72 million. This impressive gift will bring the PMC's total contributions to $972 million since 1980, positioning the organization to cross a monumental $1 billion in cumulative fundraising for the Institute in 2024.

Key Points: 
  • BOSTON, Nov. 13, 2023 /PRNewswire/ -- Today, the Pan-Mass Challenge (PMC), the world's single most successful athletic fundraiser, announced its largest gift ever for cancer research, treatment, and care at the world-renowned Dana-Farber Cancer Institute , a record-breaking $72 million.
  • This impressive gift will bring the PMC's total contributions to $972 million since 1980, positioning the organization to cross a monumental $1 billion in cumulative fundraising for the Institute in 2024.
  • "Our riders continue to expand the very definition of what a bike-a-thon, and a bicycle, was really meant to do!
  • When the PMC began in 1980, the five-year relative survival rate for cancer was 50 percent, and today, it's more than 65 percent.

Who Will You Save This Childhood Cancer Awareness Month

Retrieved on: 
Friday, September 1, 2023
Ninja, Acute lymphoblastic leukemia, Who, Cancer, Wilms' tumor, Research, Heart, Dream, Grace, Child, Young Lives vs Cancer, Gunner, Challenge, Diagnosis, CCAM, Social media, Toy, Nursing, St. Baldrick's Foundation

LOS ANGELES, Sept. 1, 2023 /PRNewswire/ -- September is Childhood Cancer Awareness Month, and the St. Baldrick's Foundation – the largest charity funder of childhood cancer research grants – kicks off its "Who Will You Save?"

Key Points: 
  • LOS ANGELES, Sept. 1, 2023 /PRNewswire/ -- September is Childhood Cancer Awareness Month, and the St. Baldrick's Foundation – the largest charity funder of childhood cancer research grants – kicks off its "Who Will You Save?"
  • 60 miles in 30 days and be part of a community moving their way to Conquer Kids' Cancer!
  • Donate Now
    Childhood Cancer Awareness Month is also an exciting time for advocacy.
  • Throughout the month of September, advocates across the country will be speaking up for kids with cancer.

Dana Farber Cancer Institute’s Jimmy Fund Celebrates 75 years of Progress and Impact on May 22

Retrieved on: 
Monday, May 22, 2023
Research, General Health, Philanthropy, Pharmaceutical, Oncology, Hospitals, Fund Raising, Foundation, Clinical Trials, Science, Other Philanthropy, Health, Other Science, Truth or Consequences, Imatinib, Oxygen, Worcester Red Sox, Food and Drug Administration, Dana–Farber Cancer Institute, Wilms' tumor, Patient, Brookline Avenue, Showcase, The Jimmy Fund, Faculty, Charitable organization, Nobel Prize, Acute lymphoblastic leukemia, Multiple myeloma, Fear, Nobel Prize in Physiology or Medicine, FDA, Pan-Mass Challenge, PD-L1, Volunteering, Boston Braves, ALL, Boston Red Sox, Cancer, Charity Navigator, History, CAR, Jimmy, Lymphoma, Partnership, Clinical trial, Fenway Park, Chronic myelogenous leukemia, BCEC, Greater Boston, Herb Chambers, City, Physician, Atlanta Braves, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medicine, Iron, Pharmaceutical industry, Nursing, Television, Auction, MD, Physiology

Special anniversary events will continue throughout the summer to celebrate 75 years of the Jimmy Fund and support of cancer care and research at the #1 ranked cancer center in New England.

Key Points: 
  • Special anniversary events will continue throughout the summer to celebrate 75 years of the Jimmy Fund and support of cancer care and research at the #1 ranked cancer center in New England.
  • Not only did he get his wish, but more than $200,000 was collected and the Jimmy Fund was born.
  • Activities for the Jimmy Fund’s 75th (#JimmyFund75) anniversary include:
    Proclamation – Boston Mayor Michelle Wu will issue a City of Boston Proclamation, announcing May 22 as Jimmy Fund Day.
  • Light Boston Blue for the Jimmy Fund – Many of Boston’s most popular landmarks and structures will light up in the Jimmy Fund’s signature blue to celebrate the Jimmy Fund on the evening of May 22.

Run Rich Run: 40 Yards Closer to Helping 400,000 Kids Around the World, St. Jude Patient Runs 4.7 second 40-Yard-Dash to Benefit St. Jude Children’s Research Hospital

Retrieved on: 
Saturday, April 29, 2023
Women, Stem Cells, Other Philanthropy, Sports, Managed Care, Men, Family, Surgery, Consumer, Radiology, Oncology, Children, Entertainment, Baby, Maternity, Hospitals, Celebrity, Football, Philanthropy, Health, Fund Raising, Foundation, Fanconi anemia, Survival rate, NFL, Travel, Housing, Food, University, University of Michigan, Kidney cancer, NCI-designated Cancer Center, ALSAC, League, St. Jude Children's Research Hospital, Cancer, Eye, NFL Network, Hope, Wilms' tumor, National Cancer Institute (Egypt), Multimedia, Athlete, National Cancer Institute, Dream, Patient, Super Bowl, Child, Love, Motivation, National Football League Draft, Hospital, Leukemia, Rhabdomyosarcoma, DSM-IV codes, Jude the Apostle

Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.

Key Points: 
  • Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.
  • View the full release here: https://www.businesswire.com/news/home/20230429005038/en/
    Emmy-nominated NFL Network host Rich Eisen suited up and sprinted for St. Jude Children’s Research Hospital® this week during his annual Run Rich Run event.
  • Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

23andMe Reports FY2023 Third Quarter Financial Results

Retrieved on: 
Wednesday, February 8, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Genetics, Machine learning, Annual general meeting, Marketing, PGS, Research, Telehealth, Food, American Society of Human Genetics, Food and Drug Administration, Family, Tax, Society, ASH, Squamous cell carcinoma, Advertising, ATM, Marker beacon, Wilms' tumor, Webcast, Society for Immunotherapy of Cancer, Immunotherapy, Genome, Human genetics, CD200R1, Drug development, EBITDA, Ashkenazi Jews, SAN, National Human Genome Research Institute, Clinical trial, Keith Lemon's LemonAid, FDA, Agricultural Research Service, Consumer service, GSK, Asthma, Interim, Growth, ASHG, Johns Hopkins, SITC, NHGRI, Therapy, Simvastatin, Pharmaceutical industry, Central Europe, Adjustment

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year 2023 (FY2023), which ended December 31, 2022. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports, and in particular the only company the FDA has authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The Company has also created the world’s largest crowdsourced platform for genetic research, which it is using to pursue drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • These reports are developed by 23andMe scientists using data and insights gathered from thousands of customers who have consented to participate in our research.
  • “Our fiscal third quarter results reflect solid revenue growth in our consumer business, despite the macro-economic headwinds, and give us confidence to raise our full year financial guidance,” said Joe Selsavage, Interim Chief Financial and Accounting Officer of 23andMe.
  • 23andMe is raising its full year guidance following Q3 FY2023 results.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Wednesday, February 8, 2023 to discuss the financial results for Q3 FY2023 and report on business progress.

Neutron Therapeutics Announces Successful Generation of a Neutron Beam for BNCT at Shonan Kamakura General Hospital in Japan

Retrieved on: 
Thursday, January 12, 2023
Science, Biotechnology, Research, Oncology, General Health, Health, Hospitals, Clinical Trials, IAEA, Neutron capture therapy of cancer, PMDA, Hospital, FDA, Radiation, Wilms' tumor, Research, Doctor of Philosophy, EMA, BNCT, Medical imaging, Neutron

Neutron Therapeutics (NT), a targeted radiation oncology therapy company developing a comprehensive clinical solution for Boron Neutron Capture Therapy (BNCT), today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan.

Key Points: 
  • Neutron Therapeutics (NT), a targeted radiation oncology therapy company developing a comprehensive clinical solution for Boron Neutron Capture Therapy (BNCT), today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan.
  • “Japan has been at the forefront of the modern, accelerator-based era of BNCT therapy and is the world leader in clinical BNCT research.
  • Neutron Therapeutics’ nuBeam® system produces the highest neutron flux available, leading to substantially shorter treatment times and improved patient experience.
  • The nuBeam® neutron source is not approved for commercial or clinical use by the FDA, PMDA, EMA or other regulatory body.

Hoag First in Southern California to Launch Phase I Clinical Trial to Treat Recurrent Neuroendocrine Cancer

Retrieved on: 
Thursday, January 12, 2023
Prostate, Hospital, Cancer, Face, Neoplasm, FDA, Molecular imaging, Hoag (health network), Hoag, Patient, Actinium-225, Radiation, Clinical trial, Wilms' tumor, Recurrence, DOTATATE, Medical imaging, Lutetium (177Lu) oxodotreotide

NEWPORT BEACH, Calif., Jan. 12, 2023 /PRNewswire/ -- Hoag Memorial Hospital Presbyterian recently became the first hospital in Southern California and one of only a handful of hospitals in the world to provide patients with access to a clinical trial that is poised to change the face of cancer treatment.

Key Points: 
  • Hoag launched a phase 1 clinical trial to test the efficacy of Actinium-225 DOTATATE in treating recurrent neuroendocrine cancers.
  • Actinium-225 DOTATATE is a new molecular therapy agent that works by targeting molecules on the surface of neuroendocrine tumor cells, called somatostatin receptors.
  • After DOTATATE targets those molecules to the cancer cells, Actinium-225 releases alpha radiation to kill them.
  • Patients enrolled in the new trial are contending with a recurrence of neuroendocrine cancer after treatment with Lutathera, which works through beta radiation.

COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors

Retrieved on: 
Monday, December 19, 2022
NET, Octreotide, EC, Somatostatin, CHMP, Carcinoid syndrome, European Medicines Agency, Acromegaly, Royal commission, Person, European Directive on Traditional Herbal Medicinal Products, SSAS, Patient, Committee, Degenerative disease, European Commission, Maintenance, FDA, Union, Wilms' tumor, Committee for Medicinal Products for Human Use, EMA, COMP, Pharmaceutical industry, EU

Orphan designation in the European Union (EU) is granted by the European Commission (EC) within 30 days of a positive opinion being issued by the COMP.

Key Points: 
  • Orphan designation in the European Union (EU) is granted by the European Commission (EC) within 30 days of a positive opinion being issued by the COMP.
  • This designation provides certain regulatory and financial incentives including but not limited to product market exclusivity for ten years in the EU following regulatory approval.
  • The granting of the orphan designation in the treatment of carcinoid syndrome follows the COMP positive opinion in October 2022 recommending that the orphan designation of Mycapssa® in the treatment of acromegaly in the EU is maintained following approval of the marketing authorisation for the product.
  • Dr Joe Wiley, CEO of Amryt Pharma, commented: “The COMP positive opinion on the recommendation to grant orphan designation for Mycapssa® in the treatment of carcinoid syndrome represents a significant development for patients with carcinoid syndrome associated with neuroendocrine tumors in Europe.

Philanthropy meets the gridiron as St. Jude patients lace up for the 2022 AutoZone Liberty Bowl

Retrieved on: 
Wednesday, December 21, 2022
Football, Health, Family, Consumer, Other Philanthropy, Philanthropy, Oncology, Sports, Parenting, Children, General Health, Hospitals, Fund Raising, Foundation, AutoZone, Kidney, Brain, ALSAC, Liberty Bowl, ESPN, Acute myeloid leukemia, Disease, Face, Neoplasm, Patient, Human, Dream, The Star-Spangled Banner, Hurler syndrome, Leg, Music, Northeast Delta Dental Stadium, Wilms' tumor, Delta Dental, Hospital, Medicine, Pharmaceutical industry, Jude the Apostle

Three patients of St. Jude Children’s Research Hospital ® will take the field at the 2022 AutoZone Liberty Bowl on Dec. 28.

Key Points: 
  • Three patients of St. Jude Children’s Research Hospital ® will take the field at the 2022 AutoZone Liberty Bowl on Dec. 28.
  • AutoZone Liberty Bowl, now in its 64th year, will begin at 4:30 p.m. CT on Wednesday, Dec. 28 on ESPN.
  • And St. Jude patient Quincy, 12, will sprint across the field to retrieve the kickoff tee, a moment sponsored by Delta Dental of Tennessee, a long-time supporter of St. Jude.
  • Earlier this year, the AutoZone Liberty Bowl and The College Football Playoff Foundation announced a donation of more than $310,000 to benefit St. Jude.